KC1036

N/A

Report date: 2026/03/19 20:00:18
NME

Base Information

Drug NameKC1036
Drug Alias NameKC1036KC-1036
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionAXL receptor tyrosine kinase inhibitorsVascular endothelial growth factor receptor 2 antagonistsTyrosine-protein kinase receptor FLT3 inhibitors
TargetsAXL receptor tyrosine kinaseVascular endothelial growth factor receptor 2Tyrosine-protein kinase receptor FLT3
Therapy Area/IndicationsSolid tumoursNeoplasm MetastasisThymus Neoplasms +[8] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesBeijing Konruns Pharmaceutical Co Ltd
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesBeijing Konruns Pharmaceutical Co Ltd
Inactive CompaniesN/A
Active IndicationsSolid tumoursNeoplasm MetastasisThymus Neoplasms +[8] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A